Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 April 2020 | Story Andre Damons | Photo Supplied
During a recent training session at the ASC. From the left, front: Marisa Viljoen and Noleen Seris; back: Prof Lauren Franz, Dr Nokhutula Shabalala, and Dr David Griessel (Unit Director).

Greta Thunberg, the 17-year-old climate and environmental activist who identifies as autistic, calls her autism a superpower. And it might just be this superpower that saves the world. 

Celebrating the strengths of autism
With April being Autism Month, it is a good time to celebrate the strengths of autism, says Dr David Griessel, Director of the University of the Free State Autism Support Centre (ASC), and a registered developmental paediatrician in the UFS Department of Paediatrics and Child Health. This includes a no-nonsense, direct thinking, and ‘outside the box’ way of looking at life, which is not mired in wishful thinking and false hope.

The Autism Support Centre was initiated by Dr Griessel, who has a special interest in neonatal intensive care, perinatal care, neuro-developmental evaluation in high-risk babies, neuro-developmental behavioural problems and learning difficulties, autism spectrum disorders, and the ethics of neuro-disability. The centre is under the auspices of the ‘Make the first 1 000 days count’ project and is located on the UFS Bloemfontein Campus.

According to Dr Griessel, the current pandemic is asking questions of us as society. “Questions about what is really important to us as humans. Whether we can really keep on expanding and consuming as if tomorrow does not exist. The inconvenient fact is that our encroachment on the habitat of wild animals bring us in contact with wild animals, and although bats are very resistant to viruses, we are not,” says Dr Griessel.  

Dr Griessel says Greta does not care about social codes, and directly asks of us: “How dare you steal my dreams and my childhood with your empty words; our homes are on fire.”

Children with autism need significant support 
“If we, as so-called neuro-typical parents, caregivers, and society can accept and support them, they add to the richness and complexity of life. The first person described in the medical literature, Donald T, had a full and eventful life, but financial support and a small community who had his back, were real enablers!”

“In this time of lockdown, my thoughts go out to parents and the challenges they may face at home. There are wonderful resources available from Autism SA, which may help them navigate these uncertain times. When we listen to Greta, a thought springs up – maybe autism will save the world.” 

A first in Africa
The Early Start Denver Model (ESDM), a first in Africa, was recently presented at the ASC and is now used to support therapists, caregivers, and patients with autism and related disorders.

This model is one of the so-called naturalistic developmental behavioural interventions, which attempts to change the core features of autism. They all share the idea that normal developmental forces should drive the process of interaction between caregiver and child; this has been  to be effective in different controlled trials.

Three registered ESDM therapists, together with Prof Lauren Franz from Duke University in North Carolina as mentor, visited Bloemfontein at the end of 2019 to become accredited trainers. Colleagues from Tanzania as well as attendees from all over South Africa have visited the centre before.

The unit is also being used by two local therapists, Elize van Rensburg and Angela Correia, to achieve reliability in this therapy. Furthermore, the unit is used as a therapy centre and for ADOS (Autism Diagnostic Observation Schedule) evaluations – the gold standard for diagnosis.

 

An inside view of the Autism Support Centre on the Bloemfontein Campus of the University of the Free State (UFS).

Supporting families as caregiversAutism South Africa has adapted a guide from the Frank Porter Graham Child Development Institute at the University of North Carolina on the support of individuals with autism through uncertain times.

Individuals with autism may need additional support to process the news and adapt to the many changes.  This population may face additional challenges related to comprehension, communication, difficulty understanding abstract language, an insistence on sameness, and a greater likelihood of anxiety and depression – all of which may be exacerbated during this stressful period. 

The following seven support strategies are designed to meet the unique needs of individuals with autism during this period of uncertainty.  

• Supporting understanding
• Offering opportunities for expression
• Prioritising coping and calming skills
• Maintaining routines
• Building new routines
• Fostering connections (from a distance)
• Being aware of changing behaviours

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept